Titre :
  • HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide.
Auteur : Di Leo, Angelo ; Larsimont, Denis ; Gancberg, David ; Järvinen, Tero ; Beauduin, Marc ; Vindevoghel, Anita ; Michel, Jeffrey ; Focan, Christian ; Ries, Fernand ; Gobert, P H ; Closon-Dejardin, Marie Thérèse ; Dolci, Stella ; Rouas, Ghizlane ; Paesmans, Marianne ; Lobelle, Jean Pierre ; Isola, Jorma ; Piccart-Gebhart, Martine
Informations sur la publication : Annals of oncology, 12, 8, (page 1081-1089)
Statut de publication : Publié, 2001-08
Sujet CREF : Sciences bio-médicales et agricoles
Mots-clés MeSH : Adult
Aged
Antigens, Neoplasm
Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
Breast Neoplasms -- chemistry
Breast Neoplasms -- drug therapy
Breast Neoplasms -- surgery
Chemotherapy, Adjuvant
Confidence Intervals
Cyclophosphamide -- administration & dosage
DNA Topoisomerases, Type II, Eukaryotic -- analysis
DNA-Binding Proteins
Epirubicin -- administration & dosage
Female
Fluorouracil -- administration & dosage
Genes, erbB-2 -- genetics
Humans
Methotrexate -- administration & dosage
Middle Aged
Predictive Value of Tests
Prognosis
Receptor, erbB-2 -- analysis
Retrospective Studies
Treatment Outcome
Tumor Markers, Biological -- analysis
Note : Clinical Trial
Clinical Trial, Phase III
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langue :
  • Anglais
Identificateurs : urn:issn:0923-7534 
info:pmid/11583189